331 related articles for article (PubMed ID: 38344336)
1. The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review.
Stan SI; Biciuşcă V; Clenciu D; Mitrea A; Boldeanu MV; Durand P; Dănoiu S
Med Pharm Rep; 2024 Jan; 97(1):12-25. PubMed ID: 38344336
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
[TBL] [Abstract][Full Text] [Related]
4. [Nonalcoholic fatty liver disease].
Lemoine M; Serfaty L
Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
9. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
Le TA; Loomba R
J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
12. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
14. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
16. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
18. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
19. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Younossi ZM; Reyes MJ; Mishra A; Mehta R; Henry L
Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
[TBL] [Abstract][Full Text] [Related]
20. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
